• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cytokinetics Incorporated

    5/27/26 4:02:25 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYTK alert in real time by email
    S-8 1 d114168ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 27, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    CYTOKINETICS, INCORPORATED

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   94-3291317

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    350 Oyster Point Boulevard

    South San Francisco, CA 94080

    (Address of Principal Executive Offices, Zip Code)

    AMENDED AND RESTATED 2015 EMPLOYEE STOCK PURCHASE PLAN

    (Full title of the plan)

    Robert I. Blum

    President and Chief Executive Officer

    Cytokinetics, Incorporated

    350 Oyster Point Boulevard

    South San Francisco, CA 94080

    (650) 624-3000

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copy to:

    Aaron K. Briggs

    Gibson, Dunn & Crutcher LLP

    One Embarcadero Center, Suite 2600

    San Francisco, CA 94111

    (415) 393-8200

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,000,000 shares of the Common Stock to be issued pursuant to the Amended and Restated 2015 Employee Stock Purchase Plan (the “ESPP”). The shares of the Common Stock previously reserved for issuance under the ESPP were registered on the Registrant’s Registration Statements on Form S-8 previously filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2015 (File No. 333-206101), May 29, 2020 (File No. 333-238786), and June 3, 2024 (File No. 333-279913) (collectively, the “Prior Registration Statements”).

    This Registration Statement on Form S-8 relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the ESPP are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    Item 8. Exhibits.

     

    Exhibit No.

     

    Exhibit Description

     4.1(1)   Amended and Restated Certificate of Incorporation.
     4.2(2)   Amended and Restated Bylaws.
     4.3(3)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
     4.4(4)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
     4.5(5)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
     4.6(6)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
     4.7(7)   Certificate of Amendment of Amended and Restated Certificate of Incorporation
     4.8(8)   Specimen Common Stock Certificate.
     5.1*   Opinion of Gibson, Dunn & Crutcher LLP.
    23.1*   Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1).
    23.2*   Consent of Independent Registered Public Accounting Firm.
    24.1*   Power of Attorney (included on the signature page of this Form S-8).
    99.1(9)   Amended and Restated 2015 Employee Stock Purchase Plan.
    107*   Filing Fee Table.
     
    *

    Filed herewith.

    (1)

    Incorporated by reference to Exhibit 3.1 to the Company’s registration statement on Form S-3, registration number 333-174869, filed with the Securities and Exchange Commission on June 13, 2011.

    (2)

    Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 17, 2023.

    (3)

    Incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 4, 2011.

    (4)

    Incorporated by reference to Exhibit 5.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 25, 2013.

     

    2


    (5)

    Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 20, 2016.

    (6)

    Incorporated by reference to Exhibit 3.5 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 3, 2023.

    (7)

    Incorporated by reference to Exhibit 4.7 to the Company’s registration statement on Form S-8, registration number 333-289349, filed with the Securities and Exchange Commission on August 7, 2025.

    (8)

    Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 9, 2007.

    (9)

    Incorporated by reference to Appendix A of the Company’s definitive proxy statement, filed with the Securities

    and Exchange Commission on April 17, 2026.

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on this 27 day of May, 2026.

     

    CYTOKINETICS, INCORPORATED

     

    By:  

    /s/ Robert I. Blum

    Name:   Robert I. Blum
    Title:  

    President and Chief Executive Officer

    (Principal Executive Officer)

    POWER OF ATTORNEY

    Each person whose signature appears below appoints Robert I. Blum, Sung Lee and John Faurescu, and each of them, any of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or would do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.

     

    Signature

      

    Title

       Date

    /s/ Robert I. Blum

    Robert I. Blum

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

       May 27, 2026

    /s/ Sung Lee

    Sung Lee

      

    Executive Vice President, Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

       May 27, 2026

    /s/ John T. Henderson

    John T, Henderson, M.B., Ch. B

       Chairman of the Board of Directors    May 27, 2026

    /s/ Muna Bhanji

    Muna Bhanji

       Director    May 27, 2026

    /s/ Robert A. Harrington

    Robert A. Harrington, M.D.

       Director    May 27, 2026

    /s/ Edward M. Kaye

    Edward M. Kaye, M.D.

       Director    May 27, 2026

    /s/ Robert E. Landry

    Roberty E. Landry

       Director    May 27, 2026

     

    4


    /s/ B. Lynne Parshall

    B. Lynne Parshall, Esq.

       Director    May 27, 2026

    /s/ Wendell Wierenga

    Wendell Weirenga, Ph.D.

       Director    May 27, 2026

    /s/ Nancy J. Wysenski

    Nancy J. Wysenski

       Director    May 27, 2026
    Get the next $CYTK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYTK

    DatePrice TargetRatingAnalyst
    6/29/2026$115.00Neutral → Buy
    UBS
    5/19/2026$99.00Buy
    Citigroup
    4/10/2026$95.00Overweight
    Wells Fargo
    1/28/2026$87.00Overweight
    Barclays
    12/18/2025$95.00Neutral → Buy
    Goldman
    7/30/2025Mkt Perform
    Raymond James
    4/24/2025$55.00Overweight
    Barclays
    2/7/2025$86.00Buy
    Citigroup
    More analyst ratings

    $CYTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cytokinetics upgraded by UBS with a new price target

    UBS upgraded Cytokinetics from Neutral to Buy and set a new price target of $115.00

    6/29/26 8:52:04 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Cytokinetics with a new price target

    Citigroup initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $99.00

    5/19/26 8:30:21 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Cytokinetics with a new price target

    Wells Fargo initiated coverage of Cytokinetics with a rating of Overweight and set a new price target of $95.00

    4/10/26 8:40:13 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wysenski Nancy was granted 75 shares, increasing direct ownership by 0.22% to 33,992 units (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    7/16/26 4:35:53 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wierenga Wendell was granted 75 shares, increasing direct ownership by 0.21% to 35,563 units (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    7/16/26 4:34:25 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaye Edward M. Md was granted 151 shares, increasing direct ownership by 1% to 10,434 units (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    7/16/26 4:32:49 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cytokinetics Incorporated

    SCHEDULE 13G/A - CYTOKINETICS INC (0001061983) (Subject)

    7/8/26 10:11:21 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Cytokinetics Incorporated

    S-8 - CYTOKINETICS INC (0001061983) (Filer)

    5/27/26 4:02:25 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - CYTOKINETICS INC (0001061983) (Filer)

    5/27/26 4:00:58 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of common stock and 14,067 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June and July 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the gr

    7/17/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

    Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to Discuss Results from Late-Breaking Science Presentations SOUTH SAN FRANCISCO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three Late Breaking Science abstracts were accepted for presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany, including a Hot Line presentation of the primary results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients

    7/7/26 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common stock and 16,429 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 2,242 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in May and June, 2026, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSU

    6/17/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Leadership Updates

    Live Leadership Updates

    View All

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Names Jim Daly to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company's Board of Directors. "Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "We are pleased to welcome him to our Board and look forward to his contributi

    8/20/25 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Names Robert E. Landry to Board of Directors

    Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years. "We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medici

    2/11/25 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytokinetics Incorporated

    SC 13G - CYTOKINETICS INC (0001061983) (Subject)

    11/14/24 1:28:31 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

    SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

    11/12/24 2:21:36 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

    SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

    11/12/24 9:55:17 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Financials

    Live finance-specific insights

    View All

    Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

    U.S. Launch of MYQORZO® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance; Full Results to be Presented at Upcoming Medical Congress MYQORZO Approved by the European Commission for Adults with Symptomatic Obstructive HCM;Supplemental NDA for MAPLE-HCM Accepted for Filing by FDA with PDUFA Date of November 14, 2026 Net Product Revenues for MYQORZO of $4.8 Million for Initial Partial Quarter;~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,

    5/5/26 4:05:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

    Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key Secondary Endpoints Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced positive topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant i

    5/5/26 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026

    Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced it will report topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) on Tuesday, May 5, 2026. Following the announcement, Cytokinetics will host a conference call at 8:00 AM Eastern Time to discuss the results. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at https://ir.cytokinetics.com or the following link: ACACIA-HCM Topline Re

    5/4/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care